No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in ...

Meanwhile, Novartis has secured European approval for a subcutaneous formulation of ... with Roche's $4.3 billion blockbuster CD20 drug Ocrevus (ocrelizumab) which is given by infusion.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

As Ocrevus is given twice a year once, after two initial infusions two weeks a part, this points to a cost of just under £10,000 per infusion, although Scholtz would not give a precise figure.

Results Famotidine has been used as a continuous subcutaneous infusion (CSCI) for 15 patients at STH and SLH since October 2021. Maximum duration of use was 36 days, until death. Doses used were 20mg ...

Objectives To characterise the use of the parenteral non-steroidal anti-inflammatory drug parecoxib when given by continuous subcutaneous infusion (CSCI) in a hospice population. Clinical experience ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.